Next Article in Journal
Metronomic Chemotherapy: Changing the Paradigm That More Is Better
Previous Article in Journal
Fostering Healing through Mindfulness in the Context of Medical Practice
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 2
10.3747/co.v16i0.404
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach

by
S. K. Pal
*,
R. K. Gupta
,
G. Dosik
and
R. A. Figlin
City of Hope Comprehensive Cancer Center, Duarte, CA, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(2), 44-47; https://doi.org/10.3747/co.v16i0.404
Submission received: 10 December 2008 / Revised: 2 January 2009 / Accepted: 4 February 2009 / Published: 1 March 2009

Abstract

Numerous therapeutic options have been introduced for metastatic renal cell carcinoma (mRCC) in recent years, including monoclonal antibodies such as bevacizumab and small-molecule tyrosine kinase inhibitors such as sunitinib and sorafenib. Similarly, several other small-molecule inhibitors—including imatinib, dasatinib, and nilotinib—have been approved for the treatment of chronic myelogenous leukemia (CML). The combination of these targeted agents is an area of intense clinical investigation. Here, we describe a patient diagnosed with mRCC while on imatinib therapy for CML. Treatment of this patient with the combination of bevacizumab and imatinib led to a 6-month period of stable disease, with no treatment-related adverse events. More extensive clinical exploration of this combination of agents may therefore be warranted.
Keywords: imatinib; bevacizumab; renal cell carcinoma; chronic myelogenous leukemia; erlotinib imatinib; bevacizumab; renal cell carcinoma; chronic myelogenous leukemia; erlotinib

Share and Cite

MDPI and ACS Style

Pal, S.K.; Gupta, R.K.; Dosik, G.; Figlin, R.A. Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach. Curr. Oncol. 2009, 16, 44-47. https://doi.org/10.3747/co.v16i0.404

AMA Style

Pal SK, Gupta RK, Dosik G, Figlin RA. Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach. Current Oncology. 2009; 16(2):44-47. https://doi.org/10.3747/co.v16i0.404

Chicago/Turabian Style

Pal, S. K., R. K. Gupta, G. Dosik, and R. A. Figlin. 2009. "Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach" Current Oncology 16, no. 2: 44-47. https://doi.org/10.3747/co.v16i0.404

APA Style

Pal, S. K., Gupta, R. K., Dosik, G., & Figlin, R. A. (2009). Concomitant Renal Cell Carcinoma and Chronic Myelogenous Leukemia: Use of a Targeted Approach. Current Oncology, 16(2), 44-47. https://doi.org/10.3747/co.v16i0.404

Article Metrics

Back to TopTop